New details about the first ChatGPT io device emerge from the iyO trademark lawsuit - here’s what you need to know.

Court filings in a trademark case against OpenAI reveal some of the company's early work on developing AI devices.

OpenAI has removed mentions of the io purchase from its website, but the ChatGPT hardware is still on the table - here’s what ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating ...

The latest price target for IO Biotech (NASDAQ:IOBT) was reported by HC Wainwright & Co. on April 1, 2025. The analyst firm set a price target for $12.00 expecting IOBT to rise to within 12 months ...

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, ...

"IO Biotech continues to make meaningful progress developing novel cancer therapies that are designed to address significant unmet needs in melanoma and other hard-to-treat cancers, and we are ...

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference. IO Biotech - GlobeNewswire - Tue May 20, 7:05AM CDT.